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Abstract 
Aims 
To assess the utility of the metabolic syndrome (MetS) and a diabetes predicting model (DPM) as 
predictors of incident diabetes. 
Methods 
A longitudinal survey was conducted in Mauritius in 1987 (n=4,972; response 80%) and 1992 
(n=3,685; follow-up 74.2%). Diabetes status was retrospectively determined using 1999 WHO criteria. 
MetS was determined according to four definitions and sensitivity, positive predictive value (PPV), 
specificity and the association with incident diabetes before and after adjustment for MetS components 
calculated.  
Results 
Of the 3,198 at risk, 297 (9.2%) developed diabetes between 1987 and 1992. The World Health 
Organization (WHO) MetS definition had the highest prevalence (20.3%), sensitivity (42.1%) and 
PPV (26.8%) for prediction of incident diabetes, the strongest association with incident diabetes after 
adjustment for age and sex (OR 4.6 (3.5-6.0)) and was the only definition to show a significant 
association after adjustment for its component parts (in men only). The low prevalence and sensitivity 
of the International Diabetes Federation (IDF) and ATPIII MetS definitions resulted from waist 
circumference cut-points that were high for this population, particularly among men, and both were not 
superior to a diabetes predicting model on ROC analysis. 
Conclusions 
Of the MetS definitions tested, the WHO definition best identifies those who go on to develop 
diabetes, but is not often used in clinical practice. If cut-points or measures of obesity appropriate for 
this population were used, the IDF and ATPIII MetS definitions could be recommended as useful tools 
for prediction of diabetes given their relative simplicity. 
Keywords  
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Introduction 1 
The Metabolic Syndrome (MetS), a clustering of metabolic abnormalities related to increased risk of 2 
cardiovascular disease (CVD) and type 2 diabetes (DM), has been the subject of interest and debate 3 
surrounding its name, composition, underlying cause, practical use and suggested management. Both 4 
insulin resistance and central obesity have been suggested as being underlying factors for the MetS, 5 
resulting in publication of multiple competing definitions. 6 
 7 
One of the primary justifications for the development of the MetS as a clinical tool is the ability to 8 
predict incident type 2 diabetes. Largely due to the difficulty in confirming incidence of diabetes, less 9 
information is available to support this capability compared to the abundance of data looking at the 10 
prediction of CVD. Of the published reports examining the MetS and incident type 2 diabetes (including 11 
cohorts from Finland, the United States, Scotland and China [1-9]), few used an OGTT at baseline and 12 
follow-up, most were not population based, in many cases the cohort used was both small and restricted 13 
in age and only two conducted comprehensive analyses using previously published MetS definitions. Of 14 
these, one was based on a cohort of middle aged men [1], while the other was conducted in a small, 15 
middle aged, non-population-based cohort [4].  16 
 17 
The longitudinal Mauritius study provides a valuable opportunity to examine the ability of four MetS 18 
definitions (ATPIII [10], World Health Organization (WHO) [11], European Group for the study of 19 
Insulin Resistance (EGIR) [12] and International Diabetes Federation (IDF) [13]), as well as a Diabetes 20 
Predicting Model (DPM) [14] and individual glucose measurements to predict diabetes identified using 21 
an OGTT, in a population based, multi-ethnic national sample. 22 
 23 
24 
 4 
Methods 25 
The population of Mauritius is 70% Asian Indians (both Hindus and Muslims), 2% Chinese and 28%  26 
from predominantly African ancestry (Creoles) with varying amounts of European, Malagasy and Indian 27 
admixture. We have previously reported the high prevalence of diabetes in Mauritius [15]. The methods 28 
have been reported in detail elsewhere [15-19]. All persons over 24 years of age living in selected areas 29 
were invited to attend a survey in 1987 and the response rate was 80%. Of the 4,972 non-pregnant 30 
participants with diabetes data surveyed in 1987, 3,685 (74.1%) were followed up in 1992. Those not 31 
able to be followed up in 1992 were older (44.7 years vs. 42.6 years) and more likely to be Creole 32 
(30.0% vs. 25.4%) or Chinese (14.6% vs. 6.0%) than those who completed both the 1987 and 1992 33 
surveys (p<0.05). No significant differences for sex or fasting and 2h-post-load glucose values were 34 
observed between those who completed the 1987 survey only and those who completed both the 1987 35 
and 1992 surveys. The survey protocol was reviewed and approved by the Alfred Healthcare Group 36 
Ethics Committee (Melbourne, Australia) as well as the Ministry of Health, Mauritius. 37 
 38 
Survey procedures 39 
A 75g OGTT was administered after overnight fast to those not taking glucose lowering medication. In 40 
both 1987 and 1992 surveys, plasma glucose was measured on-site using a YSI glucose analyzer 41 
(Yellow Springs, OH, USA) within 3 hours of collection, with quality controls measured several months 42 
later in Newcastle upon Tyne at the reference laboratory, which is a member of the Wellcome quality 43 
assurance scheme. Following transport on dry ice to Newcastle-upon-Tyne, fasting insulin was 44 
measured in serum, using a modification of the method of Soeldner and Slone [20]. Inter-assay and 45 
intra-assay coefficients of variation were 4% and 6% respectively. Cross-reactivity with intact proinsulin 46 
and 32,33-split proinsulin was 27% and 16% respectively. There was less than 5% difference between 47 
results obtained with this assay and a highly specific immunosorbent assay. 48 
 49 
 5 
Glucose tolerance status was determined according to 1999 WHO criteria and persons taking either 50 
insulin or oral hypoglycaemic agents were also classified as having diabetes [11]. HDL cholesterol and 51 
triglycerides were determined from fasting serum by manual enzymatic methods. Blood pressure (BP) 52 
was measured with a standard mercury sphygmomanometer. Height and weight were measured in light 53 
clothing without shoes. Waist circumference was measured at the horizontal level between the 54 
xiphisternum and umbilicus yielding the minimum measurement [21]. Hip circumference was taken as 55 
the horizontal measure around the pelvis at the point of maximal protrusion of the buttocks.  Waist and 56 
hip circumference and BP were measured twice, and the mean calculated. If duplicate waist or hip 57 
measurements differed by >2 cm, a third was taken and the mean of the closest two calculated.  58 
 59 
Definitions of the MetS 60 
The four definitions of the MetS used are shown in Table 1. It should be noted that microalbuminuria 61 
was not measured in this study, and assumed to be negative for the WHO definition. 62 
 63 
Statistical analyses 64 
Analyses were conducted using SPSS version 11.5.1 (SPSS Inc., Chicago, Illinois, USA) and Stata 9.0 65 
(StataCorp, College Station, Texas, USA). Insulin resistance for the EGIR MetS definition was 66 
calculated as the top quartile of fasting plasma insulin values in the non-diabetic population at the 1987 67 
survey. The modified homeostatic model was used to estimate insulin sensitivity (HOMA%S) [22]. The 68 
bottom quartile of HOMA%S in the whole population at 1987 was used to estimate insulin resistance for 69 
the WHO MetS definition. The DPM was calculated based on the method described by Stern et al [14]. 70 
Independent samples t-tests were used to compare differences in the prevalence of the MetS between 71 
ethnic groups, and comparisons of baseline characteristics for those identified by the four MetS 72 
definitions (comparisons made between individuals not contained in both groups). Logistic regression 73 
was used to estimate odds ratios for incident diabetes. Annualized diabetes incidence was calculated 74 
using the formula -ln(1-S)/t, where S = proportion of new cases (number of new cases at follow-75 
 6 
up/number of cases at risk at baseline) and t = the time of follow-up. Of the 3,685 participants, 3,665 76 
(99%) could be classified for all four MetS definitions. Pregnant women and those without a diabetes 77 
status at either 1987 or 1992 were excluded from all analyses. 78 
 79 
Results 80 
Of the 3,685 participants, 487 (13.2%) had known or newly diagnosed diabetes in 1987. Including them, 81 
the MetS prevalence in 1987 varied between 14.1% (95% CI 13.0-15.3) (IDF) and 20.4% (19.1-21.7) 82 
(WHO), with ATPIII (19.6%, 18.3-20.9) being intermediate.  83 
 84 
The prevalence of the MetS in 1987 among the same group after exclusion of those with diabetes was 85 
WHO 14.6% (13.4-15.8), ATPIII 14.2% (13.0-15.4), IDF 10.7% (9.6-11.7) and EGIR 9.2% (8.2-10.2).  86 
There was considerable overlap in the individuals identified as having the MetS by the WHO, ATPIII 87 
and IDF MetS definitions, with 6.7% of the sample in 1987 (around 1 in 4 of those identified by any 88 
definition) being identified by all of these  (Figure 1). The prevalence of the ATPIII, IDF and EGIR 89 
MetS definitions were significantly higher among Creoles (19.2% (16.4-21.9), 14.2% (11.8-16.6) and 90 
11.6% (9.4-13.8) respectively) than Indians (12.2% (10.8-13.6), 9.5% (8.2-10.7) and 8.4% (7.3-9.6) (all 91 
p<0. 05)). No significant difference in the prevalence of the WHO defined MetS were observed between 92 
the three major ethnic groups (Indian, Creole and Chinese) and ethnicity was not a significant covariate 93 
in regression analysis of incident diabetes and each of the the MetS definitions tested (all p>0.1). 94 
 95 
Of the 3,685 participants, 46.4% were male, mean age was 42.8±12.7 years, BMI 23.8± 4.3kg/m2, waist 96 
circumference 76.5±10.5 cm, weight 58.9±12.1kg, systolic/diastolic BP 127±20 / 78±12 mmHg, HDL 97 
cholesterol 1.28±0.33 mmol/L, fasting plasma glucose 5.7±1.9 mmol/L and geometric mean 98 
triglycerides 1.3±1.3 mmol/L. Major differences in parameters between those identified by each of the 99 
MetS definitions include those identified by the IDF MetS comprising 22.9% men, compared with 100 
53.0% for WHO (p<0.001), and the higher BMI of those identified by the IDF MetS definition 101 
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(29.3kg/m2) than those identified by either the WHO (27.2 kg/m2) or ATPIII definitions (27.0 kg/m2) 102 
(p<0.001).  103 
 104 
Incidence and prediction of diabetes 105 
297 (9.3%) participants developed diabetes between 1987 and 1992, with the annual incidence being 106 
19.5/1000 population. The incidence varied from 11.2/1000 among those not identified by any MetS 107 
definition, to 62.5/1000 for those identified by the WHO MetS definition (Table 2). The OR for 108 
development of diabetes over five years was higher for WHO (OR (95%CI) 4.6 (3.5-6.0)), than for 109 
ATPIII (3.1 (2.3-4.0)), IDF (3.0 (2.2-4.2)) or EGIR (3.2 (2.3-4.3)). Changing the reference group from 110 
those without the MetS defined by a single criterion to those without the MetS defined by any of the 111 
four criteria (such that there is a comparable reference group for each definition), the OR for WHO is 112 
still greater (WHO 5.3 (4.0-7.0), ATPIII 4.1 (3.1-5.6), IDF 4.1 (3.0-5.8)), EGIR 4.5 (3.2-6.3). After 113 
replacing the obesity criteria of ATPIII and IDF with that used in the WHO MetS definition, the age and 114 
sex adjusted OR for incident diabetes increased to 4.0 (3.1-5.1) and 3.7 (2.9-4.8) respectively, and 4.4 115 
(3.3-5.7) and 4.6 (3.5-6.0) when the reference group was those without the MetS defined by any of the 116 
four criteria. Of the individual components of the MetS examined, the OR for incident diabetes was 117 
highest for the glucose component of the WHO MetS definition (5.0 (3.8-6.5)).  118 
 119 
Analysis of sensitivity and specificity for identification of incident diabetes using the MetS as well as its 120 
components are presented in Tables 3 and 4 and in Figure 2. The low sensitivity and prevalence of the 121 
IDF MetS definition was largely due to the low prevalence of the obesity component of this definition 122 
(using waist circumference), despite the use of ethnicity dependent cut-points. For men in particular, a 123 
large increase in sensitivity (IDF, 16.0% to 55.6%; ATPIII, 38.9% to 55.3%) with only a moderate 124 
decrease of PPV was seen in both the IDF and ATPIII MetS definitions when either the obesity criteria 125 
were substituted by that used in the WHO MetS definition, or when the waist cut-point was reduced for 126 
Indians and Chinese to ≥80cm (M) or ≥70cm (F). Further investigation of the relationship between 127 
 8 
obesity and incident diabetes revealed a strong, positive association between quintiles of each of waist 128 
circumference, BMI and WHR and incident cases of diabetes for both men and women (p<0.001), 129 
further suggesting that the inability of the obesity components of the IDF and ATPIII definitions to 130 
predict incident diabetes was largely a result of the waist circumference cut-points for males, rather than 131 
the measure itself (Table 5). Of the obesity measures, WHR had a stronger association with incident 132 
diabetes than either waist circumference or BMI. 133 
 134 
From the plot with the MetS as well as receiver operating characteristic (ROC) curves for fasting and 2-135 
hour glucose and the probability of developing diabetes derived from the DPM (Figure 2), it is clear that 136 
in their published form, the ATPIII, IDF and EGIR MetS definitions are no better than fasting glucose 137 
alone for prediction of diabetes. When the ATPIII or IDF MetS definitions with obesity criteria 138 
substituted to that of WHO are used, they join the WHO MetS definition in being slightly above the 139 
curve for fasting glucose, and with similar properties to 2-hour glucose or the DPM. 140 
 141 
Association between the MetS and diabetes after adjustment for MetS 142 
components 143 
Each of the MetS definitions had highly significant odds ratios of three or greater for incident diabetes 144 
(Table 6). In men but not women, after adjustment for their components (as well as for age, sex and 145 
family history of diabetes) only the WHO MetS definition maintained a statistically significant odds 146 
ratio (1.8 (1.1-2.8)). 147 
 148 
Discussion 149 
In this examination of the ability of the MetS to predict incident diabetes over five years in a mixed 150 
Asian/Creole population-based sample, we have shown that (despite its practical limitations) the WHO 151 
definition had superior predictive capabilities due to the use of WHR in defining obesity in this 152 
definition. The performance of the ATPIII and IDF MetS definitions, both of which are in common 153 
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usage and use ethnicity specific cut-points for obesity, improved considerably when their obesity criteria 154 
were substituted with that used in the WHO definition. In their published form, both were no better than 155 
the use of an individual fasting glucose measurement. The use of the DPM was at least as good as any of 156 
the MetS definitions in identifying incident cases of diabetes. Of the four definitions tested, only that of 157 
the WHO remained statistically significant after adjustment for each of its components, as well as age, 158 
sex, ethnicity and family history. This result is suggestive of either a significant interaction between the 159 
components and/or the influence of factors not included in the definition including the possibility of an 160 
underlying abnormality (such as insulin resistance) not directly or perfectly measured or alternatively, 161 
suboptimally measured or modelled component variables. 162 
 163 
The IDF definition’s sensitivity varied considerably with sex. While the prevalence and sensitivity are 164 
both high among women, they are extremely low among men, largely due to the inability of the waist 165 
circumference cut-points used to identify obese individuals (despite ethnicity being taken into account as 166 
recommended in the IDF definition) and obesity being the central feature of this definition. Only 7.7% 167 
of men were identified as obese by the IDF MetS criteria (the ATPIII definition identified 6.9%), 168 
meaning that this is the upper limit for the overall prevalence of the IDF MetS. While the EGIR and 169 
ATPIII definitions both use waist circumference to define obesity, with relatively high cut-points, in 170 
neither of these definitions is obesity an essential component. Using the WHO obesity criteria of 171 
elevated BMI and/or waist-hip ratio, 38.1% are identified as obese. This, together with the fact that of 172 
the 297 who went on to develop diabetes, 163 (54.9%) were male, suggests that waist circumference 173 
using IDF (particularly since it assigns priority to obesity in the definition), EGIR and ATPIII cut-points 174 
was an inappropriate measure of obesity in this population. Changing the obesity measure in the IDF 175 
MetS definition to that used by WHO increases sensitivity to 46%, higher than that achieved by any of 176 
the other definitions tested, further emphasizing this point. The strong positive relationship between 177 
waist circumference and incident diabetes observed suggests that waist circumference can be a good 178 
predictor of incident diabetes and that the cut-points chosen, rather than the measure itself is limiting the 179 
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predictive ability of the IDF definition in particular. Waist circumference in men increased between the 180 
subsequent surveys in Mauritius from an average of 77.7 cm in 1987 to 86.3 cm in 1992 and 86.5 cm in 181 
1998 (these surveys included both a follow-up of the 1987 cohort as well as additional subjects), 182 
suggesting that Mauritius in 1987 may have been at a stage immediately prior to transition to a more 183 
western lifestyle. Previously, we have shown that both WHR and BMI independently predict type 2 184 
diabetes in this population [23]. 185 
 186 
Whether a single glucose measurement is more valuable as a diabetes prediction tool than the more 187 
complex MetS definition or other predicting models is an interesting public health question. The ROC 188 
curve analysis suggests that a single fasting glucose measurement may be comparable to the MetS as a 189 
diabetes risk prediction tool, with the DPM providing slightly better predictive ability. Both have the 190 
inherent benefit of being a continuous rather than dichotomous measure. While there is a danger in 191 
relying on a single parameter to measure diabetes risk due to population specific distribution differences, 192 
the complexity of diagnosing the MetS or using risk equations such as the DPM means that many 193 
doctors and other health workers, particularly in countries other than the most technologically advanced, 194 
are unlikely to use such devices. 195 
 196 
Several reports have now been published demonstrating the ability of the MetS to predict CVD and 197 
overall mortality [24-27], however the Framingham risk equation has been shown to be more effective 198 
in predicting both coronary heart disease and stroke [7]. For type 2 diabetes, the evidence for the 199 
predictive ability of the MetS is much stronger, but conflicting. The WHO definition has been shown to 200 
have a higher sensitivity and PPV than ATPIII in a cohort of middle aged Finish men [1]. From the 201 
conclusions of the American San Antonio Heart[2] and Insulin Resistance Atherosclerosis Studies 202 
(IRAS)[4], that comprised more obese populations, the opposite is true, with ATPIII being at least as 203 
good as WHO. Interestingly, the IRAS study also evaluated the IDF definition, which was found to be 204 
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not significantly different to WHO as a predictor of diabetes, emphasizing the impact of population-205 
specific characteristics on the ability of the MetS to predict diabetes. 206 
 207 
Recently, several risk scores for the identification of asymptomatic or incident type 2 diabetes have been 208 
developed [28]. These have included various demographic, anthropometric, behavioural and 209 
biochemical parameters. The predictors and in particular their classification varies among different 210 
populations and ethnic groups. For instance, the simple, inexpensive and non-invasive Finnish Diabetes 211 
Risk Score (which unfortunately could not be applied to this dataset) has been reported as having an 212 
area-under-the-curve in ROC analysis of 10-year diabetes risk as high as 0.85 [29]. The advantage of 213 
such a score is that even a lay person can estimate their probability of developing type 2 diabetes. Risk 214 
scores should also be to some extent population specific, in particular regarding the cut-points for 215 
anthropometric variables [30]. The DPM used here has been demonstrated to be valid in this analysis 216 
even though it was based on data from an ethnically different population. 217 
 218 
It should be noted that the WHO MetS definition used the bottom quartile of HOMA%S to estimate 219 
insulin resistance (reducing variability in the prevalence of insulin resistance due to population specific 220 
prevalence differences) due to the absence of a euglycaemic clamp, and microalbuminuria was not 221 
measured. In addition, these results cannot be generalized to other population groups and the baseline 222 
study was conducted almost 20 years ago, meaning that the prevalence of the MetS and its ability to 223 
predict diabetes in the current Mauritius population are likely to be different. Finally, response to follow-224 
up was 74.2%, with significant differences between responders and non-responders in ethnicity and age 225 
but not sex or glucose values, meaning that the sample was population based, but not necessarily 226 
representative of the population. 227 
 228 
An important justification for the creation of the MetS is its use as a clinical tool predicting incident 229 
diabetes among diverse populations. In this population of predominantly South Asian ancestry, both the 230 
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ATPIII and IDF MetS definitions proved to be poor predictors of diabetes because of the very low waist 231 
circumference in this population, even among those categorised as obese by WHR. An individual fasting 232 
glucose measurement was superior to both definitions and neither was found to be independent of their 233 
component parts. The WHO definition, which uses WHR in its obesity criteria was both a better 234 
predictor of diabetes, and in men was independent of its components. The DPM was shown to be at least 235 
as good as any of the MetS definitions tested at identifying incident cases of diabetes.236 
 237 
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TABLES & FIGURES 
Table 1. Definitions of the MetS used in this report. 
WHO 1999 [11] EGIR 1999 [12] ATPIII 2005 [10] IDF[13] 
Glucose intolerance, IGT or diabetes and/or 
insulin resistancea 
Insulin resistance (defined as 
hyperinsulinaemia – top 25% of fasting insulin 
values among the non-diabetic population  
 Central obesity - waist circumference ≥90 cm (M) (or 94 cm if Creole) or ≥80 cm (F) 
Plus 2 or more of the following Plus 2 or more of the following 3 or more of the following Plus 2 or more of the following 
1. Obesity: BMI>30 kg/m2 or 
WHR >0.9 (M) >0.85 (F) 
2. Dyslipidaemia: Triglycerides ≥1.7 
mmol/l or HDL cholesterol <0.9 
mmol/L (M) <1.0 mmol/L (F) 
 
 
 
3. Hypertension: BP ≥140/90 mmHgb 
4. Microalbuminuriab : urinary 
albumin excretion rate ≥ 20µg min-
1 or albumin:creatinine ratio ≥30 
mg g-1 
1. Central obesity: Waist circumference 
≥94 cm (M), ≥80 cm (F) 
2. Dyslipidaemia: Triglycerides >2.0 
mmol/L or HDL cholesterol <1.0  
mmol/L or on treatment for this 
abnormalityb 
 
 
3. Hypertension: BP ≥140/90 mmHg 
and/or medication  
4. Fasting plasma glucose ≥6.1mmol/L 
1. Central obesity: Waist circumference 
≥102 cm (M), ≥88 cm (F)c 
2. Hypertriglyceridaemia: Triglycerides 
≥1.7 mmol/L or on treatment for this 
abnormalityb 
3. Low HDL cholesterol: <1.03 mmol/L 
(M), <1.29 mmol/L (F) or on 
treatment for this abnormalityb 
4. Hypertension: BP ≥130/85 mmHg 
and/or medication 
5.  Fasting plasma glucose ≥5.6 mmol/L 
 
 
1. Triglycerides ≥1.7 mmol/L or 
treatment for this abnormalityb 
2. Low HDL cholesterol: <1.03 mmol/L 
(M), <1.29 mmol/L (F) or treatment 
for this abnormalityb 
 
3. Hypertension: BP ≥130/85 mmHg or 
medication  
4. Fasting plasma glucose ≥5.6 mmol/L 
or previously diagnosed type 2 
diabetes 
a Due to the absence of a measure of insulin resistance using a euglycaemic clamp, the bottom quartile of HOMA%S was used to define insulin resistance for the WHO MetS   
b For this analysis, the WHO definition of hypertension included treatment for this condition; urinary albumin was not measured, so is assumed to be normal; Treatment for 
dyslipidaemia was not assessed, as required for the EGIR, IDF and ATPIII definitions, so was also assumed to be absent. 
c The 2005 update to the NCEP ATPIII MetS definition specifies that waist circumference of ≥80cm (F) and ≥90cm (M) are to be used for Asian Americans – these cut-points have 
been adopted for Chinese and South Asian participants in this analysis. 
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Table 2. Incidence of diabetes 1987-1992 in Mauritius from those with the MetS and its component 
abnormalities. 
 
Abnormality MetS definition abnormality is part of n (%)
† 
Annual DM 
incidence/1000 
population 
OR for DM, 
adjusted for age 
and sex 
 MetS  
WHO 466 (14.6) 62.5 4.6 (3.5-6.0)** 
ATPIII 452 (14.1) 48.9 3.1 (2.3-4.0)** 
EGIR 294 (9.2) 50.8 3.2 (2.3-4.3)** 
IDF 340 (10.6) 46.8 3.0 (2.2-4.2)** 
IDF (with WHO obesity) 605 (18.9) 51.4 3.7 (2.9-4.8)** 
ATPIII (with WHO obesity) 761 (23.8) 48.2 4.0 (3.1-5.1)** 
Obesity 
WHO 1018 (31.8) 37.3 2.8 (2.2-3.6)** 
ATPIII 490 (15.4) 35.2 2.4 (1.8-3.2)** 
IDF 592 (18.5) 33.8 2.4 (1.8-3.2)** 
Lipids 
WHO 1073 (33.6) 30.1 2.1 (1.7-2.7)** 
IDF/ATPIII triglycerides 829 (25.9) 34.4 2.3 (1.8-3.0)** 
IDF/ATPIII HDL cholesterol 1231 (38.5) 21.6 1.4 (1.1-1.8)* 
Blood pressure IDF/ATPIII 1220 (38.1) 31.5 2.1 (1.6-2.7)** 
EGIR/WHO 735 (23) 38.6 2.2 (1.7-2.9)** 
Glucose/insulin 
WHO 1157 (36.2) 40.5 5.0 (3.8-6.5)** 
EGIR (insulin) 837 (26.2) 31.2 2.3 (1.8-3.0)** 
EGIR (glucose) 268 (8.4) 69.8 4.4 (3.3-6.0)** 
ATPIII/IDF 803 (25.1) 43.5 3.3 (2.6-4.3)** 
Total 3198 (100.0%) 19.5 n/a 
* p<0.01 **p<0.001 
a Excludes those with diabetes at baseline. Percentage is of the total population. 
b Referent group is those without the individual state/abnormality 
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Table 3. Sensitivity, specificity, PPV and NPV of the MetS for the detection of incident diabetes between 
1987-1992 in Mauritius. 
 
Diabetes, 1987-1992 WHO ATPIII EGIR IDF 
IDF with 
WHO obesity 
ATPIII with 
WHO obesity 
IDF with 
reduced WCa 
Sensitivity 
Total 42.1 38.9 22.4 24.0 46.4 55.3 49.8 
Men 46.6 39.1 17.9 16.0 55.6 63.6 45.7 
Women 36.6 38.6 27.8 33.8 35.3 45.1 54.9 
Specificity 
Total 88.2 85.0 92.1 90.7 83.8 79.3 79.2 
Men 86.5 86.1 93.5 96.0 80.1 75.4 83.7 
Women 89.7 84.0 90.9 86.2 86.9 82.6 75.3 
PPV 
Total 26.8 20.8 22.4 20.9 22.6 21.4 19.6 
Men 29.7 25.5 25.2 32.9 25.5 24.0 25.5 
Women 23.3 16.9 20.7 17.2 18.7 18.1 15.9 
NPV 
Total 93.7 93.2 92.1 92.1 93.9 94.6 93.9 
Men 93.0 92.1 90.3 90.3 93.6 94.4 92.6 
Women 94.3 94.2 93.7 93.9 94.1 94.7 95.2 
Prevalence 
(baseline) 
Total 14.6 17.2 9.2 10.7 19.0 23.9 23.5 
Men 17.1 16.6 7.7 5.3 23.8 28.9 19.5 
Women 12.3 17.8 10.5 15.4 14.8 19.5 27.0 
a IDF with waist circumference ≥80  cm (M) (or 94 cm if Creole) or ≥70 cm (F)
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Table 4. Sensitivity, specificity, PPV and NPV of components of the MetS for the detection of diabetes in Mauritius 1987-1992. 
 
DM 87-92 
B
M
I>
30
 k
g/
m
2  o
r W
H
R
 >
0.
9 
(M
) 
>0
.8
5 
(F
) (
W
H
O
) 
W
ai
st
 c
irc
um
fe
re
nc
e 
 
 
 
10
2c
m
 if
 C
re
ol
e)
;  
 
 
 
88
cm
 if
 C
re
ol
e)
 (A
TP
II
I)
 
W
ai
st
 c
irc
um
fe
re
nc
e 
 
) (
or
 
94
cm
 if
 C
re
ol
e)
 o
r 
 
 
 
Tr
ig
ly
ce
rid
es
 
 
 
 
 
ch
ol
es
te
ro
l <
0.
9m
m
ol
/L
 (M
) 
<1
.0
m
m
ol
/L
 (F
) (
W
H
O
) 
Tr
ig
ly
ce
rid
es
  
 
tre
at
m
en
t f
or
 th
is
 a
bn
or
m
al
ity
 (I
D
F,
 
N
C
EP
) 
H
D
L 
ch
ol
es
te
ro
l <
1.
03
 m
m
ol
/L
 (M
), 
<1
.2
9 
m
m
ol
/L
 (F
) o
r t
re
at
m
en
t (
ID
F,
 
N
C
EP
) 
B
lo
od
 p
re
ss
ur
e  
 
m
ed
ic
at
io
n 
(I
D
F,
 N
C
EP
) 
B
lo
od
 p
re
ss
ur
e  
 
m
ed
ic
at
io
n 
(E
G
IR
, W
H
O
) 
IF
G
, I
G
T 
or
 in
su
lin
 re
si
st
an
ce
 (W
H
O
) 
To
p 
25
%
 o
f f
as
tin
g 
in
su
lin
 (E
G
IR
) 
Fa
st
in
g 
gl
uc
os
e 
 
 
 
Fa
st
in
g 
gl
uc
os
e 
 
 
EP
, 
ID
F)
 
Sensitivity 
Total 58.4 26.6 31.0 51.0 44.6 42.4 59.9 43.4 71.4 40.9 26.6 52.9 
Men 66.0 16.6 19.0 60.5 56.8 33.7 66.9 46.6 65.0 37.4 25.8 54.6 
Women 49.3 38.8 45.5 39.4 29.5 53.0 51.5 39.6 79.1 45.1 27.6 50.7 
Specificity 
Total 70.7 85.8 82.7 68.0 75.8 61.9 64.1 79.1 67.3 75.2 93.5 77.7 
Men 65.4 94.3 93.7 61.2 66.1 73.7 59.3 76.7 71.3 79.0 92.1 74.3 
Women 75.3 78.6 73.4 73.7 84.1 51.9 68.1 81.2 64.0 72.0 94.7 80.6 
PPV 
Total 17.0 16.1 15.5 14.0 15.8 10.2 14.6 17.6 18.3 14.5 29.5 19.6 
Men 18.9 26.5 27.2 16.0 17.0 13.6 16.8 19.7 21.8 18.0 28.6 20.6 
Women 14.6 13.4 12.8 11.3 13.5 8.6 12.1 15.2 15.8 12.0 30.6 18.3 
NPV 
Total 94.3 91.9 92.1 93.2 93.1 91.3 94.0 93.2 95.8 92.5 92.6 94.2 
Men 94.0 90.2 90.4 92.7 92.6 90.1 93.6 92.1 94.3 91.1 91.0 93.0 
Women 94.5 93.8 94.0 93.5 93.4 92.8 94.3 94.0 97.3 93.9 93.9 95.0 
Prevalence 
(baseline) 
Total 32.0 15.4 18.6 33.8 26.1 38.5 38.1 23.0 36.3 26.3 8.4 25.1 
Men 38.1 6.9 7.7 41.2 36.4 27.1 43.5 25.9 32.7 22.8 9.8 28.9 
Women 26.6 22.8 28.1 27.3 17.0 48.4 33.4 20.5 39.4 29.3 7.1 21.8 
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Table 5. OR for incident diabetes among quintiles of waist circumference, BMI and Waist:Hip ratio among men and women. 
 
  
Waist 
Circumference 
OR for DM, 
adjusted for age BMI (kg/m2) 
OR for DM, 
adjusted for age  Waist:Hip Ratio 
OR for DM, 
adjusted for age  
Men 
<69.5cm 1 <19.9 1 <0.833 1 
69.5-74.9cm 1.5 19.9-22.09 2.2 0.833-0.871 2.8 
75.0-79.9cm 2.2 22.1-24.1 2.4 0.872-0.900 3.7 
80.0-85.4cm 3.8 24.11-26.7 4.0 0.901-0.937 8.0 
>85.4cm 7.3 >26.7 7.3 >0.937 8.8 
Women 
<65.0cm 1 <19.9 1 <0.755 1 
65.0-70.74cm 2.4 19.9-22.09 1.5 0.755-0.786 3.3 
70.75-76.4cm 4.5 22.1-24.1 2.0 0.787-0.822 6.1 
76.5-83.9cm 6.3 24.11-26.7 3.6 0.823-0.869 5.2 
>83.9cm 5.8 >26.7 4.8 >0.869 8.0 
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Table 6. Sex-specific logistic regression analysis of the independence of four definitions of the MetS from 
their component parts in the as5sociation with incident diabetes over 5 years in Mauritius. 
 Model 1a Model 2b 
MetS Male Female Male Female 
WHO 5.6 (4.0-7.9) 5.0 (3.4-7.4) 1.8 (1.1-2.8) 1.3 (0.7-2.2) 
ATPIII 4.0 (2.8-5.7) 3.3 (2.3-4.8) 1.2 (0.8-1.9) 0.6 (0.4-1.1) 
EGIR 3.1 (2.0-5.0) 3.9 (2.6-5.9) 0.8 (0.4-1.4) 0.9 (0.5-1.6) 
IDF 4.6 (2.8-7.5) 3.2 (2.2-4.7) 1.3 (0.7-2.4) 0.7 (0.4-1.2) 
aModel 1 - includes only the MetS 
bModel 2 - MetS plus age, ethnicity, family history of diabetes and all MetS 
components as continuous variables (all definitions include triglycerides, 
HDL-C, diastolic bp and systolic bp; ATPIII and IDF also include FPG and 
waist; WHO also includes 2hPG, HOMA-S, BMI and WHR; EGIR also 
includes FPG, fasting insulin and waist). 
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Figure 1. Prevalence of the MetS, Mauritius 1987 (includes those with diabetes) n=3665. 
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Figure 2. Receiver operating characteristic curve for detection of undiagnosed diabetes over 5 years in 
Mauritius, using four definitions of the MetS, as well as the IDF and ATPIII MetS with obesity criteria 
substituted for that used in the WHO definition, fasting and 2-hour post load plasma glucose and the 
Diabetes Predicting Model [14]. 
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